NCT07713485 Study of XmAb412 in Healthy Participants
| NCT ID | NCT07713485 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Xencor, Inc. |
| Condition | Not Applicable - Healthy Adult Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2026-07-13 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 128 participants in total. It began in 2026-07-13 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants
Eligibility Criteria
Inclusion Criteria: * Age 18-55 years old * Must be in good health with no significant medical history * BMI 18-35 kg/m2 * Contraceptive use consistent with local regulations * Able and willing to provide written informed consent Exclusion Criteria: * Any physical condition that prohibits study completion * Known hypersensitivity to the trial intervention or any of its components * HIV, hepatitis B and hepatitis C positive * Clinically significant abnormal ECG * Use of other investigational products within 5 half lives from Screening * Blood or plasma donation within 60 days from Screening * Pregnant or breastfeeding Other protocol defined inclusion/exclusion criteria apply
Contact & Investigator
412 Study Information
✉ XmAb412-01info@xencor.com412 Study Information
STUDY DIRECTOR
Xencor, Inc.
Frequently Asked Questions
Who can join the NCT07713485 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Not Applicable - Healthy Adult Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07713485 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07713485 currently recruiting?
Yes, NCT07713485 is actively recruiting participants. Contact the research team at XmAb412-01info@xencor.com for enrollment information.
Where is the NCT07713485 trial being conducted?
This trial is being conducted at Joondalup, Australia, Nedlands, Australia.
Who is sponsoring the NCT07713485 clinical trial?
NCT07713485 is sponsored by Xencor, Inc.. The principal investigator is 412 Study Information at Xencor, Inc.. The trial plans to enroll 128 participants.